Relatlimab Injection
NDC Package 70409-7126-9

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Relatlimab injection is a bulk ingredient utilized for pharmaceutical compounding or manufacturing. This formulation utilizes a injection delivery system. Marketed by Bristol-myers Squibb Company, this product is identified by NDC 70409-7126.

Identification & Billing

NDC Package Code
70409-7126-9
Package Description
10 kg in 1 BAG
Product Code
70409-7126
11-Digit Billing Format
70409712609

Clinical Specifications

Proprietary Name
Relatlimab
Non-Proprietary Name
Relatlimab
Substance Name
Relatlimab
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Active Ingredient(s)
RELATLIMAB 1 kg/kg

Regulatory & Marketing

Labeler Name
Bristol-myers Squibb Company
Product Type
Bulk Ingredient
Marketing Category
BULK INGREDIENT - A category specifying that a product is marketed as a bulk ingredient.
Start Marketing Date
12-19-2011
Listing Expiration
12-31-2027
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70409-7126-9 identifies a specific commercial package of 10 kg in 1 bag of Relatlimab (UNFINISHED drug), a bulk ingredient labeled by Bristol-myers Squibb Company. This injection is formulated for use and contains relatlimab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bristol-myers Squibb Company on December 19, 2011. The current certification is valid through December 31, 2027.

How is this Bristol-myers Squibb Company product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70409712609. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70409-7126-9
11-Digit CMS (5-4-2)
70409-7126-09

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.